Sanofi's CEO, Chris Viehbacher was quoted in a release that Sanofi was banking on its next round of pipeline candidates, up to 19 of which may be introduced between 2012 and 2015, to fuel its top line growth by 5% CAGR. Top candidates include: Kynamro (mipomersen) for familial hypercholesterolemia, Visamerin/Mulsevo (semuloparin) for venous thrombosis, Aubagio (teruflunomide) for CVS disease, Zaltrap (aflibercept) for colon cancer, Lyxumia (lixisenatide) for type II diabetes and Lemtrada (alemtuzumab) for muscular sclerosis.
That's the plus side of the balance sheet so to speak. On the minus side, Sanofi will cut $2.9 billion more out of its costs (exclusive of Genzyme). Costs will be reduced in R&D by 12% from the spend in 2008 and headcount will be reduced by 22% from that same time period (about 3000 jobs).
Fiscal austerity becomes necessary as Sanofi faces its personal patent cliff with the patent expiration of its top sellers Plavix (blood thinner) and Avapro (high blood pressure). The top line (hopefully) will be bolstered by Viehbach's decision to spend $23 billion in acquistions over the past 2 plus years. Analyst reviews were mixed (what else is new) on the prospects of Sanofi hitting its 5% growth goals. See Fierce Biotech and Pharmalot.
Posted by Bruce Lehr Sep 7th 2011.